Europe Contraceptive Market Outlook, 2030
The Europe Contraceptive Market is segmented into by Product into (Contraceptive Drugs and Contraceptive Devices); by Age Group (15–44 years, Above 44 years); by Gender (Female, Male); by End-User (Individuals, Hospitals & Gynecology Clinics, Community Healthcare Centers); and by Distribution Channels (Retail Pharmacies, Hospital Pharmacies, Online Channels, and Others).
- Bonafide Research
- 30-06-2025
- Pages : 101
- Figures : 12
- Tables : 35
- Region : Europe
- Category : Lifescience & Healthcare
- Medical Devices
Europe contraceptive market is expected to exceed USD 10.30 billion by 2030, driven by rising female workforce and delayed parenthood.
- Historical Period2019-2023
- Base Year2024
- Forecast Period2025-2030
- Market Size (2030) USD 10.3 Billion
- Largest MarketGermany
- Fastest Market Russia
- Format
Featured Companies
- 1. Mankind Pharma Limited
- 2. Johnson & Johnson,
- 3. Reckitt Benckiser Group Plc.
- 4. Glenmark Pharmaceuticals Ltd.
- 5. Bayer AG
- 6. Merck & Co., Inc.
- More...
Contraceptive Market Analysis
The Europe contraceptive market is a dynamic and evolving sector driven by increasing awareness about family planning, rising healthcare infrastructure, and growing emphasis on reproductive health across the region. Over the past decade, the demand for contraceptives in Europe has witnessed a steady rise due to factors such as changing social attitudes towards sexual health, increased participation of women in the workforce, and the emphasis on delaying childbirth for career and personal reasons. The market is characterized by a diverse range of products, including oral contraceptives, intrauterine devices (IUDs), contraceptive implants, vaginal rings, patches, condoms, and emergency contraceptives. Among these, hormonal contraceptives like pills, patches, and vaginal rings dominate due to their effectiveness and ease of use, while non-hormonal methods, such as copper IUDs and condoms, remain significant due to preferences driven by health concerns or side effects associated with hormonal options. The European Medicines Agency (EMA) plays a crucial role in the approval and monitoring of contraceptive drugs and devices, ensuring that all products meet stringent safety standards before reaching consumers. Additionally, various national health systems often subsidize contraceptives or offer them at reduced costs, encouraging wider usage and reducing unintended pregnancies. The market also benefits from well-established distribution channels, including pharmacies, hospitals, clinics, and online platforms, making contraceptives easily accessible to a broad demographic. Innovation remains a significant driver within the European contraceptive market, with pharmaceutical and biotech companies focusing on developing novel delivery systems and formulations to enhance user convenience and minimize side effects. Recent advancements include the introduction of biodegradable implants, extended-release hormonal methods, and multipurpose technologies that combine contraception with protection against sexually transmitted infections (STIs). According to the research report "Europe Contraceptive Market Outlook, 2030," published by Bonafide Research, the Europe Contraceptive market is expected to reach a market size of more than USD 10.30 Billion by 2030. The rise in female workforce participation throughout Europe has also propelled demand for contraceptives, as many women delay childbirth to pursue education and employment opportunities, necessitating effective birth control solutions to support their lifestyle choices. Healthcare infrastructure advancements and improved access to medical services further bolster the contraceptive market. Most European countries have well-established healthcare systems with policies that either subsidize or fully cover contraceptive products, thereby lowering economic barriers and making contraception more affordable and accessible. Pharmacies, hospitals, clinics, and digital health platforms provide a wide range of distribution channels that reach urban and rural populations alike. The integration of telemedicine and online pharmaceutical services has become especially prominent in recent years, offering convenient access to contraceptives and consultation services, which has been particularly crucial during the COVID-19 pandemic when physical access to healthcare providers was limited. Europe’s diverse population includes growing immigrant communities, many of whom face distinct reproductive health challenges and needs. Tailored educational efforts and culturally sensitive healthcare services are increasingly important to address these disparities and foster contraceptive adoption. Additionally, rising rates of sexually transmitted infections (STIs) in certain regions highlight the dual demand for contraceptives that also provide STI protection, such as condoms and emerging multipurpose prevention technologies. Recent developments include long-acting reversible contraceptives (LARCs) such as hormonal IUDs and implants that offer extended protection with minimal user intervention. These products have gained popularity due to their reliability and low maintenance compared to daily oral contraceptives.
to Download this information in a PDF
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Dynamic
Market Drivers
• Increased Awareness and Education on Reproductive Health:Growing public health initiatives and education campaigns across Europe have significantly raised awareness about reproductive health and contraception. Governments, NGOs, and health organizations are actively promoting family planning, leading to a more informed population, especially among younger demographics. This has resulted in increased demand for contraceptive products such as pills, condoms, IUDs, and implants. Additionally, comprehensive sex education in schools and public health messaging have normalized the conversation around contraception, further driving adoption.• Advancements in Contraceptive Technologies:The European market is benefiting from continuous innovation in contraceptive technologies. Newer methods such as hormone-releasing intrauterine devices (IUDs), transdermal patches, and long-acting reversible contraceptives (LARCs) offer users more reliable, low-maintenance, and discreet options. These innovations are increasing consumer trust and satisfaction, especially among women looking for long-term solutions with minimal side effects. Pharmaceutical companies are also investing in R&D to improve efficacy, reduce hormonal side effects, and introduce male contraceptive options, broadening the market base.
Market Challenges
Regulatory and Access Barriers:• Despite being a progressive region, Europe still faces regulatory and access-related hurdles. The classification of some contraceptives as prescription-only restricts easy access, particularly in rural areas or among young, uninsured individuals. Regulatory discrepancies between countries, for example, varying approval processes for new contraceptive methods also hamper market entry and cross-border sales. In some conservative societies, cultural or religious opposition further impedes open access and distribution, creating a fragmented market environment.
• Concerns About Side Effects and Health Risks:Health concerns remain a major barrier to the widespread use of hormonal contraceptives. Many users are wary of the side effects such as weight gain, mood swings, and increased risk of blood clots, leading some to discontinue use or avoid hormonal options altogether. The rising demand for natural and non-hormonal alternatives has increased scrutiny of pharmaceutical products. This has forced manufacturers to invest more in research and marketing to rebuild trust, which increases operational costs and delays product launches.
Market Trends
• Growing Demand for Non-Hormonal and Eco-Friendly Options:With increasing consumer focus on wellness and sustainability, there is a growing shift toward non-hormonal and environmentally friendly contraceptives. Products such as copper IUDs, fertility tracking apps, and biodegradable condoms are gaining traction among health-conscious and eco-aware consumers. Startups and smaller players are entering the market with innovative, green solutions, appealing particularly to Gen Z and millennial users who prioritize holistic and ethical consumption.• Digital Health Integration and Telemedicine:Digital transformation is reshaping the contraceptive landscape in Europe. Telemedicine platforms and mobile health apps now offer virtual consultations, online prescriptions, and discreet home delivery of contraceptives. This is particularly appealing in urban areas and among tech-savvy users who value convenience and privacy. Integration of AI and data analytics in fertility tracking apps is also helping women make more informed choices about contraception, thereby enhancing user engagement and long-term market growth.
Contraceptive Segmentation
| By Product | Contraceptive Drugs (Contraceptive Pills, Topical,Injectable) | |
| Contraceptive Devices (Condom, Vaginal Ring, Subdermal Implants, Diaphragms,Sponges,IUDs) | ||
| By Age Group | 15 - 44 years | |
| Above 44 years | ||
| By Gender | Female | |
| Male | ||
| By End-User | Individuals | |
| Hospitals & Gynecology Clinics | ||
| Community Healthcare Centers | ||
| By Distribution Channels | Retail pharmacies | |
| Hospital pharmacies | ||
| Online channels | ||
| Other distribution channels | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Russia | ||
Contraceptive devices are the fastest-growing product type in the European contraceptive industry due to increasing demand for long-acting, low-maintenance, and hormone-free birth control options supported by progressive healthcare systems and informed consumer choices. Devices such as copper IUDs and hormonal implants provide extended protection ranging from three to ten years, making them highly attractive to individuals seeking reliable, reversible contraception without the need for constant attention. This trend is particularly strong in countries with robust healthcare systems such as Germany, France, and the Nordic nations where public health policies and insurance plans often cover or subsidize the cost of device-based contraceptives, making them more accessible to a wider population. Additionally, Europe’s strong focus on patient education and informed decision-making has empowered women to consider more sustainable contraceptive methods that fit their lifestyle and health goals. Healthcare professionals across Europe are also more likely to recommend LARCs (long-acting reversible contraceptives) as first-line options due to their superior efficacy and lower risk of user error compared to short-term methods like pills or condoms. The rising preference for hormone-free contraception, such as copper IUDs, also aligns with the continent’s broader emphasis on natural wellness and minimal medical intervention. Moreover, Europe has seen a rise in environmental consciousness and skepticism toward pharmaceuticals, further boosting the appeal of reusable and long-lasting contraceptive devices. Another key factor is the increasing autonomy and involvement of women in family planning decisions, supported by gender-equal policies and sexual health education, which has created a favorable environment for exploring device-based methods. Market players are also introducing innovative, user-friendly designs, including smaller IUDs and biodegradable implants, which improve comfort and reduce side effects addressing previous concerns that limited uptake. This innovation, combined with strong clinical support, has significantly accelerated adoption rates. The 15–44 years age group is the largest in Europe’s contraceptive industry due to widespread sexual health education, high contraceptive awareness, and proactive family planning practices among reproductive-age individuals. In Europe, the 15–44 years age group dominates the contraceptive industry, primarily because it encompasses the core reproductive years where the need for birth control is both biologically and socially most relevant. This age range includes teenagers becoming sexually active, young adults delaying parenthood, and individuals or couples planning families strategically—factors that collectively create sustained demand for contraceptive products and services. European countries are known for their comprehensive sexual health education, often introduced in schools at an early age, which fosters a culture of awareness and responsibility regarding contraception and reproductive choices. As a result, individuals within this demographic are more informed about their options, including hormonal pills, IUDs, implants, condoms, and emergency contraceptives. This awareness translates into high rates of contraceptive use and consistent market demand. Additionally, societal norms across Europe increasingly support delayed marriage and parenthood, with many people choosing to focus on education, careers, and personal development throughout their 20s and into their 30s. This trend extends the period during which effective contraception is essential, often leading to sustained usage over many years. The widespread availability of modern healthcare systems, often subsidized or provided through public healthcare, ensures easy access to contraceptive methods for most of the population, further reinforcing usage among this age group. Moreover, family planning is highly integrated into European public health policy, with strong government and institutional support for reproductive autonomy, which encourages individuals to manage their fertility according to personal and economic circumstances. Digital platforms and telehealth services have also made it easier for people within this age range to consult with healthcare providers and obtain prescriptions, enhancing convenience and continuity of use. The female gender segment leads the European contraceptive industry due to comprehensive healthcare systems offering a wide range of accessible female contraceptive options, reinforced by progressive social attitudes supporting women’s reproductive autonomy. In Europe, the female contraceptive market holds a leading position largely because of well-developed healthcare infrastructures that ensure broad access to an extensive variety of female contraceptive methods. European countries, particularly those in Western and Northern Europe, have universal or highly subsidized healthcare systems that facilitate affordable and convenient access to contraception, ranging from oral contraceptive pills, intrauterine devices (IUDs), hormonal implants, vaginal rings, to emergency contraception. This accessibility ensures that women have multiple options to choose from, enabling them to select contraceptives that best suit their medical needs, lifestyle preferences, and family planning goals. These healthcare systems often integrate contraceptive counseling into routine gynecological and general health services, which reinforces the use of female contraceptive methods as a standard component of reproductive health care. Moreover, Europe’s progressive social attitudes and strong advocacy for women’s rights play a crucial role in maintaining the dominance of the female contraceptive segment. Across much of the continent, there is broad societal support for women’s reproductive autonomy, gender equality, and sexual health education. This environment encourages women to take active control over their fertility choices and seek contraceptive solutions proactively. The strong presence of public health campaigns, educational programs, and NGOs focused on empowering women further strengthens demand for female contraceptives. Women are often more informed about the available contraceptive options and feel socially supported in their decisions regarding birth control. Government policies and family planning programs also significantly contribute to the prominence of female contraceptives in Europe. Many European countries have implemented national initiatives aimed at reducing unintended pregnancies and promoting reproductive health, often prioritizing female contraceptive access. In Europe, hospitals and gynecology clinics are the fastest-growing end-user segment in the contraceptive industry due to increasing demand for personalized reproductive healthcare, advances in medical technology, and comprehensive government-supported family planning programs. The growth of hospitals and gynecology clinics as the fastest expanding end-user category within Europe’s contraceptive industry is largely driven by a combination of heightened demand for personalized, professional reproductive healthcare and progressive healthcare policies. European populations increasingly prioritize individualized contraceptive solutions tailored to their specific medical histories and lifestyle needs. This trend has led to a shift away from over-the-counter or pharmacy-based contraceptive purchases toward more specialized medical settings such as hospitals and gynecology clinics, where expert consultation and monitoring can be provided. Patients seek reassurance and safety in contraceptive choices, especially as many options—including hormonal methods, long-acting reversible contraceptives (LARCs) such as implants and IUDs, and novel contraceptive technologies—require medical assessment, prescription, or insertion by trained professionals. Europe also benefits from advanced healthcare infrastructure, with well-established hospital networks and specialized gynecology clinics that provide comprehensive reproductive health services. These institutions are equipped with the latest medical technologies and staffed by highly trained specialists who can offer counseling, follow-up care, and management of side effects, making them trusted venues for contraceptive provision. Moreover, the integration of contraceptive services into broader healthcare frameworks such as sexual and reproductive health clinics enhances access and convenience for patients, contributing to rising utilization rates. Government policies and public health initiatives across many European countries actively promote family planning and reproductive health education, further supporting the shift toward hospital- and clinic-based contraceptive services. Many national healthcare systems subsidize or fully cover contraceptive methods when provided through medical facilities, incentivizing users to seek care in these settings. Additionally, Europe’s aging population and evolving demographics have increased focus on women’s health services, including contraception, stimulating demand in hospitals and specialized clinics. Retail pharmacies lead the contraceptive distribution channel in Europe due to their widespread accessibility, trusted professional presence, and ability to offer a broad range of products conveniently within local communities. Retail pharmacies dominate the contraceptive distribution landscape in Europe because they uniquely combine convenience, accessibility, and trust, meeting the needs of a diverse and health-conscious population. Across European countries, retail pharmacies are highly integrated into daily life, often located in easily accessible urban and suburban areas, making them the go-to destination for a wide range of healthcare products, including contraceptives. Their strategic presence allows consumers to purchase contraceptives quickly without the need for hospital visits or navigating more complex healthcare systems. Additionally, retail pharmacies operate with extended hours compared to hospitals and clinics, catering to consumers who seek flexibility around their schedules. This accessibility is complemented by the professional guidance offered by pharmacists, who are highly trained and able to provide counseling on contraceptive options, proper usage, and potential side effects. This trusted interaction helps bridge the gap between prescription requirements and self-care, empowering consumers to make informed decisions confidently. Moreover, retail pharmacies in Europe typically stock an extensive assortment of contraceptive products, ranging from over-the-counter options like condoms and emergency contraceptives to prescription medications such as birth control pills and hormonal patches. This breadth of choice within a single, convenient location enhances customer satisfaction and loyalty. Pharmacies also benefit from established relationships with healthcare providers and insurance companies, facilitating smoother prescription fulfillment and reimbursement processes, which further encourages consumers to use retail channels for contraceptive needs. The leading role of retail pharmacies is also supported by European regulatory frameworks and healthcare policies that promote access to contraceptives through community-based outlets. Many countries encourage pharmacy involvement in sexual health education and preventive care, which has led to the implementation of pharmacy-led initiatives such as contraceptive counseling, vaccinations, and screening programs.
to Download this information in a PDF
Contraceptive Market Regional Insights
Germany leads the European contraceptive industry due to its strong healthcare system, extensive government support for reproductive health, and a highly developed pharmaceutical sector driving innovation and accessibility. Germany’s position as a leader in the European contraceptive industry stems from its robust healthcare infrastructure, proactive public health policies, and a well-established pharmaceutical and medical technology sector that fosters innovation. The country’s universal healthcare system ensures that contraceptives are widely accessible and often reimbursed or subsidized through statutory health insurance schemes, making family planning affordable for a broad segment of the population. This comprehensive coverage reduces financial barriers that might otherwise limit contraceptive use, encouraging higher adoption rates and fostering a stable market. Additionally, Germany’s government places significant emphasis on sexual and reproductive health education, supporting initiatives aimed at increasing public awareness and dismantling social stigmas associated with contraceptive use. These educational programs, integrated into school curricula and community outreach efforts, empower individuals with knowledge to make informed reproductive choices from a young age. Beyond accessibility and education, Germany’s pharmaceutical industry is a critical driver of its leadership in the contraceptive market. Renowned for its research and development capabilities, Germany hosts many leading companies specializing in the production of contraceptive drugs and devices, including hormonal contraceptives, intrauterine devices (IUDs), and novel delivery systems. This focus on innovation has led to the introduction of advanced, safe, and user-friendly contraceptive options that appeal to diverse demographic groups, further expanding the market. The country also benefits from a strong regulatory framework that ensures high standards for safety and efficacy, thereby boosting consumer confidence and adoption rates. Social and demographic trends play a complementary role, as German society increasingly prioritizes family planning and reproductive autonomy, reflected in delayed childbearing and smaller family sizes.
to Download this information in a PDF
Companies Mentioned
- Mankind Pharma Limited
- Johnson & Johnson,
- Reckitt Benckiser Group Plc.
- Glenmark Pharmaceuticals Ltd.
- Bayer AG
- Merck & Co., Inc.
- Lupin Limited
- Pfizer Inc.
- AbbVie Inc.
- Church & Dwight Co., Inc.
- The Cooper Companies Inc.
- Exeltis
Table of Contents
- 1. Executive Summary
- 2. Market Dynamics
- 2.1. Market Drivers & Opportunities
- 2.2. Market Restraints & Challenges
- 2.3. Market Trends
- 2.3.1. XXXX
- 2.3.2. XXXX
- 2.3.3. XXXX
- 2.3.4. XXXX
- 2.3.5. XXXX
- 2.4. Supply chain Analysis
- 2.5. Policy & Regulatory Framework
- 2.6. Industry Experts Views
- 3. Research Methodology
- 3.1. Secondary Research
- 3.2. Primary Data Collection
- 3.3. Market Formation & Validation
- 3.4. Report Writing, Quality Check & Delivery
- 4. Market Structure
- 4.1. Market Considerate
- 4.2. Assumptions
- 4.3. Limitations
- 4.4. Abbreviations
- 4.5. Sources
- 4.6. Definitions
- 5. Economic /Demographic Snapshot
- 6. Europe Contraceptive Market Outlook
- 6.1. Market Size By Value
- 6.2. Market Share By Country
- 6.3. Market Size and Forecast, By Product
- 6.4. Market Size and Forecast, By Age Group
- 6.5. Market Size and Forecast, By Gender
- 6.6. Market Size and Forecast, By End-User
- 6.7. Market Size and Forecast, By Distribution Channels
- 6.8. Germany Contraceptive Market Outlook
- 6.8.1. Market Size by Value
- 6.8.2. Market Size and Forecast By Product
- 6.8.3. Market Size and Forecast By Age Group
- 6.8.4. Market Size and Forecast By Gender
- 6.8.5. Market Size and Forecast, By Distribution Channels
- 6.9. United Kingdom (UK) Contraceptive Market Outlook
- 6.9.1. Market Size by Value
- 6.9.2. Market Size and Forecast By Product
- 6.9.3. Market Size and Forecast By Age Group
- 6.9.4. Market Size and Forecast By Gender
- 6.9.5. Market Size and Forecast, By Distribution Channels
- 6.10. France Contraceptive Market Outlook
- 6.10.1. Market Size by Value
- 6.10.2. Market Size and Forecast By Product
- 6.10.3. Market Size and Forecast By Age Group
- 6.10.4. Market Size and Forecast By Gender
- 6.10.5. Market Size and Forecast, By Distribution Channels
- 6.11. Italy Contraceptive Market Outlook
- 6.11.1. Market Size by Value
- 6.11.2. Market Size and Forecast By Product
- 6.11.3. Market Size and Forecast By Age Group
- 6.11.4. Market Size and Forecast By Gender
- 6.11.5. Market Size and Forecast, By Distribution Channels
- 6.12. Spain Contraceptive Market Outlook
- 6.12.1. Market Size by Value
- 6.12.2. Market Size and Forecast By Product
- 6.12.3. Market Size and Forecast By Age Group
- 6.12.4. Market Size and Forecast By Gender
- 6.12.5. Market Size and Forecast, By Distribution Channels
- 6.13. Russia Contraceptive Market Outlook
- 6.13.1. Market Size by Value
- 6.13.2. Market Size and Forecast By Product
- 6.13.3. Market Size and Forecast By Age Group
- 6.13.4. Market Size and Forecast By Gender
- 6.13.5. Market Size and Forecast, By Distribution Channels
- 7. Competitive Landscape
- 7.1. Competitive Dashboard
- 7.2. Business Strategies Adopted by Key Players
- 7.3. Key Players Market Positioning Matrix
- 7.4. Porter's Five Forces
- 7.5. Company Profile
- 7.5.1. AbbVie, Inc.
- 7.5.1.1. Company Snapshot
- 7.5.1.2. Company Overview
- 7.5.1.3. Financial Highlights
- 7.5.1.4. Geographic Insights
- 7.5.1.5. Business Segment & Performance
- 7.5.1.6. Product Portfolio
- 7.5.1.7. Key Executives
- 7.5.1.8. Strategic Moves & Developments
- 7.5.2. Bayer AG
- 7.5.3. Reckitt Benckiser Group plc
- 7.5.4. Mankind Pharma Limited
- 7.5.5. Exeltis
- 7.5.6. Pfizer, Inc.
- 7.5.7. The Cooper Companies, Inc.
- 7.5.8. Glenmark Pharmaceuticals Limited
- 7.5.9. Johnson & Johnson
- 7.5.10. Merck & Co., Inc.
- 7.5.11. Lupin Limited
- 7.5.12. Church & Dwight Co., Inc.
- 8. Strategic Recommendations
- 9. Annexure
- 9.1. FAQ`s
- 9.2. Notes
- 9.3. Related Reports
- 10. Disclaimer
Table 2: Influencing Factors for Contraceptive Market, 2024
Table 3: Top 10 Counties Economic Snapshot 2022
Table 4: Economic Snapshot of Other Prominent Countries 2022
Table 5: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 6: Europe Contraceptive Market Size and Forecast, By Product (2019 to 2030F) (In USD Million)
Table 7: Europe Contraceptive Market Size and Forecast, By Age Group (2019 to 2030F) (In USD Million)
Table 8: Europe Contraceptive Market Size and Forecast, By Gender (2019 to 2030F) (In USD Million)
Table 9: Global Contraceptive Market Size and Forecast, By End-User (2019 to 2030F) (In USD Million)
Table 10: Global Contraceptive Market Size and Forecast, By Distribution Channels (2019 to 2030F) (In USD Million)
Table 11: Germany Contraceptive Market Size and Forecast By Product (2019 to 2030F) (In USD Million)
Table 12: Germany Contraceptive Market Size and Forecast By Age Group (2019 to 2030F) (In USD Million)
Table 13: Germany Contraceptive Market Size and Forecast By Gender (2019 to 2030F) (In USD Million)
Table 14: Global Contraceptive Market Size and Forecast, By Distribution Channels (2019 to 2030F) (In USD Million)
Table 15: United Kingdom (UK) Contraceptive Market Size and Forecast By Product (2019 to 2030F) (In USD Million)
Table 16: United Kingdom (UK) Contraceptive Market Size and Forecast By Age Group (2019 to 2030F) (In USD Million)
Table 17: United Kingdom (UK) Contraceptive Market Size and Forecast By Gender (2019 to 2030F) (In USD Million)
Table 18: Global Contraceptive Market Size and Forecast, By Distribution Channels (2019 to 2030F) (In USD Million)
Table 19: France Contraceptive Market Size and Forecast By Product (2019 to 2030F) (In USD Million)
Table 20: France Contraceptive Market Size and Forecast By Age Group (2019 to 2030F) (In USD Million)
Table 21: France Contraceptive Market Size and Forecast By Gender (2019 to 2030F) (In USD Million)
Table 22: Global Contraceptive Market Size and Forecast, By Distribution Channels (2019 to 2030F) (In USD Million)
Table 23: Italy Contraceptive Market Size and Forecast By Product (2019 to 2030F) (In USD Million)
Table 24: Italy Contraceptive Market Size and Forecast By Age Group (2019 to 2030F) (In USD Million)
Table 25: Italy Contraceptive Market Size and Forecast By Gender (2019 to 2030F) (In USD Million)
Table 26: Global Contraceptive Market Size and Forecast, By Distribution Channels (2019 to 2030F) (In USD Million)
Table 27: Spain Contraceptive Market Size and Forecast By Product (2019 to 2030F) (In USD Million)
Table 28: Spain Contraceptive Market Size and Forecast By Age Group (2019 to 2030F) (In USD Million)
Table 29: Spain Contraceptive Market Size and Forecast By Gender (2019 to 2030F) (In USD Million)
Table 30: Global Contraceptive Market Size and Forecast, By Distribution Channels (2019 to 2030F) (In USD Million)
Table 31: Russia Contraceptive Market Size and Forecast By Product (2019 to 2030F) (In USD Million)
Table 32: Russia Contraceptive Market Size and Forecast By Age Group (2019 to 2030F) (In USD Million)
Table 33: Russia Contraceptive Market Size and Forecast By Gender (2019 to 2030F) (In USD Million)
Table 34: Global Contraceptive Market Size and Forecast, By Distribution Channels (2019 to 2030F) (In USD Million)
Table 35: Competitive Dashboard of top 5 players, 2024
Figure 2: Market attractiveness Index, By Region 2030
Figure 3: Market attractiveness Index, By Segment 2030
Figure 4: Europe Contraceptive Market Size By Value (2019, 2024 & 2030F) (in USD Million)
Figure 5: Europe Contraceptive Market Share By Country (2024)
Figure 6: Germany Contraceptive Market Size By Value (2019, 2024 & 2030F) (in USD Million)
Figure 7: United Kingdom (UK) Contraceptive Market Size By Value (2019, 2024 & 2030F) (in USD Million)
Figure 8: France Contraceptive Market Size By Value (2019, 2024 & 2030F) (in USD Million)
Figure 9: Italy Contraceptive Market Size By Value (2019, 2024 & 2030F) (in USD Million)
Figure 10: Spain Contraceptive Market Size By Value (2019, 2024 & 2030F) (in USD Million)
Figure 11: Russia Contraceptive Market Size By Value (2019, 2024 & 2030F) (in USD Million)
Figure 12: Porter's Five Forces of Global Contraceptive Market
Contraceptive Market Research FAQs
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Our Clients
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (24 June, 2026)
- Notify To Team (24 June, 2026)
- Report updation (25 June, 2026)
- Report Quality Check (25 June, 2026)
- Report Dispatch (26 June, 2026)
- Hard Copy
Recently Viewed Products
Europe Contraceptive Market Outlook, 2030
We are friendly and approachable, give us a call.